Beeline Medicines reported that afimetoran met the primary endpoint in a global Phase II trial for adults with active moderate-to-severe SLE: all three oral dose levels produced superior SRI-4 response rates at week 48 versus placebo (p < 0.001). Secondary outcomes—including disease activity, skin and joint manifestations, steroid-sparing effects and quality of life—supported the primary result. Afimetoran was generally well tolerated with no new safety signals. Full results will be presented at an upcoming medical congress as Beeline plans pivotal development.
Beeline’s Afimetoran Hits Primary Endpoint in Global Phase II SLE Trial
The trial enrolled 248 adults aged 18 to 70 with moderate-to-severe SLE. Credit: Jarun Ontakrai / Shutterstock.com.
Beeline Medicines announced that its global Phase II clinical trial of afimetoran in adults with active moderate-to-severe systemic lupus erythematosus (SLE) met the study's primary endpoint, reinforcing the drug's potential as an oral therapeutic option for lupus patients.
Key Results
All three oral dose levels of afimetoran produced higher SLE Responder Index-4 (SRI-4) response rates at week 48 than placebo, with statistical significance in each dose group (p < 0.001). Secondary endpoints—including overall disease activity, skin and joint manifestations, corticosteroid reduction, physician global assessment and patient-reported quality of life—showed improvements consistent with the primary outcome.
Study Design and Population
The randomised, double-blind, placebo-controlled, dose-ranging trial enrolled 248 adults aged 18–70 years with active moderate-to-severe SLE despite background therapy. Participants received once-daily oral afimetoran or matching placebo in addition to standard background treatments, including corticosteroids.
Safety
Afimetoran was generally well tolerated. Safety and tolerability findings were consistent with a prior Phase I study, and no new safety signals were reported during the trial period.
Context and Next Steps
Afimetoran is a selective oral inhibitor of Toll-like receptors 7 and 8. It was discovered by researchers at Bristol Myers Squibb and licensed to Beeline Medicines in July 2025. The compound previously showed exploratory efficacy in a Phase Ib study in cutaneous lupus erythematosus and received Fast Track designation from the US Food and Drug Administration for SLE in May 2025.
Beeline said it will present full study details and additional analyses at an upcoming medical congress and intends to advance afimetoran into pivotal development.
Saqib Islam, CEO, Beeline Medicines: "Too many people with systemic lupus continue to cycle through therapies that do not adequately control their disease, leaving them with diminished quality of life and vulnerable to debilitating long-term complications."
"These positive Phase II results strengthen our conviction that afimetoran has the potential to meaningfully change the treatment landscape as a foundational oral therapy for lupus patients. We look forward to advancing our programme into pivotal development for those who urgently need new options."
Help us improve.
